D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
NBIX holding history
Neurocrine Biosciences Inc in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NBIX overviewAll 13F holders of NBIXFull Q2 2026 holdings
- Shares (Q2 2026)
- 5,599
- Value
- $943.6K
- % of portfolio
- <0.1%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 5,599 | $943.6K | <0.1% | −83,585−93.7% | Reduced | Holders |
| Q1 2026 | 89,184 | $11.7M | <0.1% | +89,184 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −14,592−100.0% | Sold out | Holders |
| Q1 2025 | 14,592 | $1.61M | <0.1% | −14,118−49.2% | Reduced | Holders |
| Q4 2024 | 28,710 | $3.92M | <0.1% | −140,744−83.1% | Reduced | Holders |
| Q3 2024 | 169,454 | $19.5M | <0.1% | +61,076+56.4% | Added | Holders |
| Q2 2024 | 108,378 | $14.9M | <0.1% | −36,902−25.4% | Reduced | Holders |
| Q1 2024 | 145,280 | $20.0M | <0.1% | +69,278+91.2% | Added | Holders |
| Q4 2023 | 76,002 | $10.0M | <0.1% | +16,940+28.7% | Added | Holders |
| Q3 2023 | 59,062 | $6.64M | <0.1% | −181,422−75.4% | Reduced | Holders |
| Q2 2023 | 240,484 | $22.7M | <0.1% | +61,378+34.3% | Added | Holders |
| Q1 2023 | 179,106 | $18.1M | <0.1% | −79,937−30.9% | Reduced | Holders |
| Q4 2022 | 259,043 | $30.9M | 0.1% | +119,781+86.0% | Added | Holders |
| Q3 2022 | 139,262 | $14.8M | <0.1% | −80,475−36.6% | Reduced | Holders |
| Q2 2022 | 219,737 | $21.4M | <0.1% | −1,196−0.5% | Reduced | Holders |
| Q1 2022 | 220,933 | $20.7M | <0.1% | +122,957+125.5% | Added | Holders |
| Q4 2021 | 97,976 | $8.35M | <0.1% | +97,976 | New | Holders |
| Q2 2021 | 0 | $0 | 0.0% | −8,732−100.0% | Sold out | Holders |
| Q1 2021 | 8,732 | $849.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.